Search company, investor...
Symetrica company logo


Founded Year



Unattributed VC - V | Alive

Total Raised


Last Raised

$5.22M | 2 yrs ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+10 points in the past 30 days

About Symetrica

Symetrica offers gamma ray spectroscopy and imaging solutions. The company's systems have been developed for security applications, medical diagnostics, geophysical applications, and space research and development.

Headquarters Location

Roman House 39 Botley Road

Southampton, England, SO52 9AE,

United Kingdom


Missing: Symetrica's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Symetrica's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Symetrica

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Symetrica is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,605 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

Symetrica Patents

Symetrica has filed 18 patents.

The 3 most popular patent topics include:

  • Artificial neural networks
  • Classification algorithms
  • Machine learning
patents chart

Application Date

Grant Date


Related Topics




Radioactivity, Radiation protection, Nuclear physics, Ionising radiation detectors, Luna program


Application Date


Grant Date



Related Topics

Radioactivity, Radiation protection, Nuclear physics, Ionising radiation detectors, Luna program



Latest Symetrica News

CEO of WMD detection firm retires after 17 years

Jun 9, 2021

CEO of WMD detection firm retires after 17 years Posted on June 9, 2021 by Jonathan Symcox share The CEO of a radiation tech firm which helps to identify weapons of mass destruction is to retire after 17 years with the company. Heddwyn Davies has built Southampton-based Symetrica into a global leader in the detection and identification of radioactive threats. The firm utilises machine learning to provide ‘world-leading performance’ and low through-life costs to the military and homeland security markets. “Heddwyn has done a tremendous job of building this company from a small UK University startup into a recognised world leader in radiation detection systems, products and technology,” said Chairman David Price. “In his 17 years at Symetrica, he led the commercial, technical and organizational development, both in the UK and the USA, to create a broad portfolio of best-in-class fixed, mobile and handheld monitoring equipment and established these products and associated software systems within the global homeland security market. “Over the last few years, the company has achieved many notable successes: securing key contracts for the provision of hand-held devices to a wide range of US and European government customers, including our most recent award of a $35 million contract to supply the Verifinder hand-held sensors to the US Department of Defense.”   Davies is succeeded by Eric Zanin, who will become the Group Chief Executive Officer immediately and will principally be located at the firm’s US facility in Westford, Massachusetts. Zanin has held global executive positions in business development and general management with Analogic Corporation and Leidos Corporation’s Security Detection and Automation operation. He has extensive experience in leading security technology innovation – most notably the introduction of computed tomography at aviation security checkpoints. Zanin added: “I am honoured to become Symetrica’s new CEO. The company has exceptional technology and scientific leadership in radiation detection. “I look forward to leading two strong teams in Southampton and Westford, MA in extending the product portfolio to new applications in the global security market. “I offer my sincere thanks to Heddwyn for positioning Symetrica for success.”  Latest Stories

Symetrica Frequently Asked Questions (FAQ)

  • When was Symetrica founded?

    Symetrica was founded in 2002.

  • Where is Symetrica's headquarters?

    Symetrica's headquarters is located at Roman House, Southampton.

  • What is Symetrica's latest funding round?

    Symetrica's latest funding round is Unattributed VC - V.

  • How much did Symetrica raise?

    Symetrica raised a total of $10.65M.

  • Who are the investors of Symetrica?

    Investors of Symetrica include Parkwalk Advisors, Nesta, Albion Capital, Technology Venture Partners (UK), Wyvern Fund and 5 more.

  • Who are Symetrica's competitors?

    Competitors of Symetrica include Dilon Technologies, SFC Fluidics, EndoChoice, Celula, BioImagene and 13 more.

Compare Symetrica to Competitors

Digital Medics

Digital Medics GmbH is a producer of technology in the area of radiology software and equipment.

Real-time Radiography

Real-Time Radiography is developing the direct Digital Radiography (DR) detectors based on its mercuric iodide x-ray photoconductor technology.nThe detector's exceptional sensitivity to x-rays, cost advantages, and low-voltage operation allow it to provide high image quality at low doses of radiation and at reduced expense to the end user. RTR is focused on bringing to market the digital x-ray imaging technology for medical, industrial, and security applications.

Gendex Corporation

Engages in the research and development, production and distribution of imaging equipment for the dental market. Gendex offers radiology and imaging products, including panoramic x-ray, intraoral x-ray, digital imaging, cameras and software.


Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.

m2m Imaging

Corp.m2m Imaging, with offices in USA and Australia produce's high-definition imaging and work flow solutions for life science applications in the MRI, PET, CT and SPECT analytical, preclinical and clinical research environments. m2m's MRI coil and accessory portfolio consists of products that have provided solutions to enable otherwise unobtainable results for research applications all over the world.

Mirabilis Medical

Mirabilis Medica is in clinical development of a non-invasive therapeutic ultrasound platform with an initial application to the treatment of uterine fibroids. The Mirabilis platform uses high resolution ultrasound imaging to localize treatment, and an ultrasound technology to quickly and non-invasively treat tissue deep in the body.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.